PGRMC1：一种用于乳腺癌雌激素受体的新型生物标志物。
PGRMC1: a new biomarker for the estrogen receptor in breast cancer.
作者信息
Craven Rolf J
出版信息
Breast Cancer Res. 2008;10(6):113. doi: 10.1186/bcr2191. Epub 2008 Nov 24.
Abstract
Estrogen receptor (ER) status is a critical biomarker in breast cancer, in large part because the ER is the target of tamoxifen and similar drugs. In the previous issue of Breast Cancer Research, Neubauer and colleagues used a proteomic approach to identify proteins that are differentially regulated by ER in breast tumors. The authors showed that ER-negative tumors have elevated levels of PGRMC1 (progesterone receptor membrane component-1), a hormone receptor component and binding partner for P450 proteins. In contrast, PGRMC1 was phosphorylated in ER-positive tumors. The staining patterns of ER and PGRMC1 were mutually exclusive in breast tumor sections, and PGRMC1 staining was sharply increased in hypoxic areas of the tumor. The results suggest that PGRMC1 is a candidate biomarker for ER status and hypoxia in breast cancer.
摘要
雌激素受体（ER）状态是乳腺癌中的一个关键生物标志物，很大程度上是因为ER是他莫昔芬及类似药物的作用靶点。在上一期的《乳腺癌研究》中，诺伊鲍尔及其同事采用蛋白质组学方法来鉴定在乳腺肿瘤中受ER差异调节的蛋白质。作者表明，ER阴性肿瘤中孕酮受体膜成分-1（PGRMC1）水平升高，PGRMC1是一种激素受体成分，也是细胞色素P450蛋白的结合伴侣。相比之下，PGRMC1在ER阳性肿瘤中发生磷酸化。在乳腺肿瘤切片中，ER和PGRMC1的染色模式相互排斥，且PGRMC1染色在肿瘤的缺氧区域急剧增加。结果表明，PGRMC1是乳腺癌中ER状态和缺氧的候选生物标志物。
相似文献
1
PGRMC1: a new biomarker for the estrogen receptor in breast cancer.PGRMC1：一种用于乳腺癌雌激素受体的新型生物标志物。
Breast Cancer Res. 2008;10(6):113. doi: 10.1186/bcr2191. Epub 2008 Nov 24.
2
Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1.乳腺癌蛋白质组学揭示雌激素受体状态与PGRMC1磷酸化差异之间的相关性。
Breast Cancer Res. 2008;10(5):R85. doi: 10.1186/bcr2155. Epub 2008 Oct 15.
3
Progesterone receptor membrane component 1 regulates lipid homeostasis and drives oncogenic signaling resulting in breast cancer progression.孕激素受体膜成分 1 调节脂质稳态并驱动致癌信号转导，导致乳腺癌进展。
Breast Cancer Res. 2020 Jul 13;22(1):75. doi: 10.1186/s13058-020-01312-8.
4
Increased expression of progesterone receptor membrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and negative breast cancer.孕激素受体膜成分1表达增加与雌激素受体阳性和阴性乳腺癌的侵袭性表型及不良预后相关。
Menopause. 2017 Feb;24(2):203-209. doi: 10.1097/GME.0000000000000739.
5
Crosstalk between progesterone receptor membrane component 1 and estrogen receptor α promotes breast cancer cell proliferation.孕激素受体膜成分 1 与雌激素受体 α 之间的串扰促进乳腺癌细胞增殖。
Lab Invest. 2021 Jun;101(6):733-744. doi: 10.1038/s41374-021-00594-6. Epub 2021 Apr 26.
6
Progesterone receptor membrane component 1 as a potential prognostic biomarker for hepatocellular carcinoma.孕激素受体膜成分 1 作为肝细胞癌潜在的预后生物标志物。
World J Gastroenterol. 2018 Mar 14;24(10):1152-1166. doi: 10.3748/wjg.v24.i10.1152.
7
May progesterone receptor membrane component 1 (PGRMC1) predict the risk of breast cancer?孕酮受体膜成分1（PGRMC1）能否预测乳腺癌风险？
Gynecol Endocrinol. 2016;32(1):58-60. doi: 10.3109/09513590.2015.1078303. Epub 2015 Aug 24.
8
Absence of progesterone receptor membrane component 1 reduces migration and metastasis of breast cancer.孕激素受体膜组份 1 的缺失可降低乳腺癌的迁移和转移。
Cell Commun Signal. 2021 Apr 8;19(1):42. doi: 10.1186/s12964-021-00719-w.
9
Association of circulating Progesterone Receptor Membrane Component-1 (PGRMC1) with PGRMC1 expression in breast tumour tissue and with clinical breast tumour characteristics.循环孕激素受体膜组份 1（PGRMC1）与乳腺癌组织中 PGRMC1 表达及临床乳腺癌特征的相关性。
Maturitas. 2020 Oct;140:64-71. doi: 10.1016/j.maturitas.2020.06.008. Epub 2020 Jun 15.
10
High Level of Progesteron Receptor Membrane Component 1 (PGRMC 1) in Tissue of Breast Cancer Patients is Associated with Worse Response to Anthracycline-Based Neoadjuvant Therapy.乳腺癌患者组织中高水平的孕激素受体膜成分1（PGRMC 1）与基于蒽环类药物的新辅助治疗反应较差有关。
Horm Metab Res. 2017 Aug;49(8):595-603. doi: 10.1055/s-0043-113635. Epub 2017 Jul 12.
引用本文的文献
1
Function and regulation of a steroidogenic CYP450 enzyme in the mitochondrion of Toxoplasma gondii.弓形虫线粒体中一种类固醇生成 CYP450 酶的功能和调节。
PLoS Pathog. 2023 Aug 31;19(8):e1011566. doi: 10.1371/journal.ppat.1011566. eCollection 2023 Aug.
2
The inactive X chromosome accumulates widespread epigenetic variability with age.失活的 X 染色体随年龄的增长积累了广泛的表观遗传变异性。
Clin Epigenetics. 2023 Aug 25;15(1):135. doi: 10.1186/s13148-023-01549-y.
3
Edaravone and mitochondrial transfer as potential therapeutics for vanishing white matter disease astrocyte dysfunction.依达拉奉和线粒体转移作为治疗进行性脑白质病星形胶质细胞功能障碍的潜在疗法。
CNS Neurosci Ther. 2023 Sep;29(9):2481-2497. doi: 10.1111/cns.14190. Epub 2023 Mar 27.
4
QSAR-Based Computational Approaches to Accelerate the Discovery of Sigma-2 Receptor (S2R) Ligands as Therapeutic Drugs.基于定量构效关系的计算方法加速 sigma-2 受体 (S2R) 配体作为治疗药物的发现。
Molecules. 2021 Aug 30;26(17):5270. doi: 10.3390/molecules26175270.
5
miRNome and Functional Network Analysis of PGRMC1 Regulated miRNA Target Genes Identify Pathways and Biological Functions Associated With Triple Negative Breast Cancer.PGRMC1调控的miRNA靶基因的miRNome和功能网络分析确定与三阴性乳腺癌相关的途径和生物学功能。
Front Oncol. 2021 Jul 19;11:710337. doi: 10.3389/fonc.2021.710337. eCollection 2021.
6
Crosstalk between progesterone receptor membrane component 1 and estrogen receptor α promotes breast cancer cell proliferation.孕激素受体膜成分 1 与雌激素受体 α 之间的串扰促进乳腺癌细胞增殖。
Lab Invest. 2021 Jun;101(6):733-744. doi: 10.1038/s41374-021-00594-6. Epub 2021 Apr 26.
7
A Potential Mechanism Underlying the Therapeutic Effects of Progesterone and Allopregnanolone on Ketamine-Induced Cognitive Deficits.孕酮和别孕烯醇酮对氯胺酮诱导的认知缺陷治疗作用的潜在机制
Front Pharmacol. 2021 Mar 8;12:612083. doi: 10.3389/fphar.2021.612083. eCollection 2021.
8
Progesterone receptor membrane associated component 1 enhances obesity progression in mice by facilitating lipid accumulation in adipocytes.孕激素受体膜相关成分 1 通过促进脂肪细胞脂质积累促进小鼠肥胖进展。
Commun Biol. 2020 Sep 4;3(1):479. doi: 10.1038/s42003-020-01202-x.
9
Progesterone receptor membrane component 1 promotes the growth of breast cancers by altering the phosphoproteome and augmenting EGFR/PI3K/AKT signalling.孕激素受体膜成分 1 通过改变磷酸化蛋白质组并增强 EGFR/PI3K/AKT 信号转导促进乳腺癌的生长。
Br J Cancer. 2020 Oct;123(8):1326-1335. doi: 10.1038/s41416-020-0992-6. Epub 2020 Jul 24.
10
The crucial role of multiomic approach in cancer research and clinically relevant outcomes.多组学方法在癌症研究及临床相关结果中的关键作用。
EPMA J. 2018 Feb 21;9(1):77-102. doi: 10.1007/s13167-018-0128-8. eCollection 2018 Mar.
本文引用的文献
1
Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1.乳腺癌蛋白质组学揭示雌激素受体状态与PGRMC1磷酸化差异之间的相关性。
Breast Cancer Res. 2008;10(5):R85. doi: 10.1186/bcr2155. Epub 2008 Oct 15.
2
Regulation of ovarian cancer cell viability and sensitivity to cisplatin by progesterone receptor membrane component-1.孕激素受体膜组分-1对卵巢癌细胞活力及顺铂敏感性的调控
J Clin Endocrinol Metab. 2008 May;93(5):1592-9. doi: 10.1210/jc.2007-2771. Epub 2008 Mar 4.
3
Predictive markers in breast cancer--the present.乳腺癌中的预测性标志物——现状
Histopathology. 2008 Jan;52(1):82-90. doi: 10.1111/j.1365-2559.2007.02897.x.
4
Progesterone receptor membrane component-1 (PGRMC1) is the mediator of progesterone's antiapoptotic action in spontaneously immortalized granulosa cells as revealed by PGRMC1 small interfering ribonucleic acid treatment and functional analysis of PGRMC1 mutations.孕酮受体膜成分-1（PGRMC1）是孕酮在自发永生化颗粒细胞中抗凋亡作用的介质，这是通过PGRMC1小干扰核糖核酸处理和PGRMC1突变的功能分析揭示的。
Endocrinology. 2008 Feb;149(2):534-43. doi: 10.1210/en.2007-1050. Epub 2007 Nov 8.
5
Hypoxia and breast cancer: prognostic and therapeutic implications.缺氧与乳腺癌：预后及治疗意义
Cell Mol Life Sci. 2007 Dec;64(24):3233-47. doi: 10.1007/s00018-007-7390-6.
6
Regulation of iron homeostasis mediated by the heme-binding protein Dap1 (damage resistance protein 1) via the P450 protein Erg11/Cyp51.由血红素结合蛋白Dap1（抗损伤蛋白1）通过P450蛋白Erg11/Cyp51介导的铁稳态调节。
J Biol Chem. 2007 Dec 14;282(50):36543-51. doi: 10.1074/jbc.M706770200. Epub 2007 Oct 22.
7
Progesterone receptor membrane component 1: an integrative review.孕激素受体膜成分1：综合综述
J Steroid Biochem Mol Biol. 2007 Jun-Jul;105(1-5):16-36. doi: 10.1016/j.jsbmb.2007.02.002. Epub 2007 May 16.
8
Dap1/PGRMC1 binds and regulates cytochrome P450 enzymes.Dap1/PGRMC1结合并调节细胞色素P450酶。
Cell Metab. 2007 Feb;5(2):143-9. doi: 10.1016/j.cmet.2006.12.009.
9
Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy.多种乳腺癌表型的基因表达谱及对新辅助化疗的反应
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):819-26. doi: 10.1158/1078-0432.CCR-05-1447.
10
Overexpression of the cytochrome p450 activator hpr6 (heme-1 domain protein/human progesterone receptor) in tumors.肿瘤中细胞色素P450激活剂hpr6（血红素-1结构域蛋白/人孕激素受体）的过表达。
Tumour Biol. 2005 May-Jun;26(3):142-6. doi: 10.1159/000086485. Epub 2005 Jun 20.
Zotero 插件